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Background Trypanosoma brucei gambiense (Tbg) causes
human African trypanosomiasis (HAT), one of the neglected
tropical diseases targeted for elimination. Integration of diagno-
sis and case management into the general health system,
sustainable monitoring of eliminated foci and development of
safe and efﬁcacious drugs, remain important challenges.
Methods The DiTECT-HAT project tackles these challenges.
For passive case detection, we will determine the diagnostic per-
formance and cost of rapid diagnostic tests (RDTs) performed
on clinical suspects in peripheral health centres, whether or not
combined with serological and/or molecular tests on ﬁlter paper
done at regional reference centres. Cost-effective diagnostic
algorithms with high positive predictive values might allow
test-and-treat scenarios without the need for complicated para-
sitological conﬁrmations. Secondly, health workers performing
house to house visits in foci with very low HAT prevalence can
easily collect blood on ﬁlter paper and send it to regional HAT
reference centres for analysis. The feasibility and cost of diag-
nostic algorithms with RDTs, serological and molecular high-
throughput tests for post-elimination monitoring will be deter-
mined. An appropriate threshold will be established to trigger
active case ﬁnding to avoid re-emergence of HAT, without
unnecessarily raising the alarm. Finally, the accuracy of neop-
terin and RNA detection as early test-of-cure will be determined
in therapeutic trials.
Earlier treatment outcome assessment will speed up the devel-
opment of new drugs for HAT, and improve management of
relapses in routine care.
Results An update of ongoing and planned activities is given.
The passive case detection sub-project is being set up in DR
Congo, Côte d’Ivoire and Guinea. The inclusions for the early
test-of-cure sub-project are ongoing in DR Congo.
Conclusions The proposed research will provide evidence to
support policies for improved HAT diagnosis and patient man-
agement within a context of disease elimination, and will con-
tribute to successful and sustainable HATelimination.
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